These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19152220)

  • 1. Current in vitro and in silico models of blood-brain barrier penetration: a practical view.
    Vastag M; Keseru GM
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):115-24. PubMed ID: 19152220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
    Adenot M; Perriere N; Scherrmann JM; Lahana R
    Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery and in vitro models of the blood-brain barrier.
    Cucullo L; Aumayr B; Rapp E; Janigro D
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):89-99. PubMed ID: 15679176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods to assess drug permeability across the blood-brain barrier.
    Nicolazzo JA; Charman SA; Charman WN
    J Pharm Pharmacol; 2006 Mar; 58(3):281-93. PubMed ID: 16536894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models for predicting blood-brain barrier permeation.
    Nielsen PA; Andersson O; Hansen SH; Simonsen KB; Andersson G
    Drug Discov Today; 2011 Jun; 16(11-12):472-5. PubMed ID: 21513815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.
    Cucullo L; Hossain M; Rapp E; Manders T; Marchi N; Janigro D
    Epilepsia; 2007 Mar; 48(3):505-16. PubMed ID: 17326793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery.
    Vandenhaute E; Sevin E; Hallier-Vanuxeem D; Dehouck MP; Cecchelli R
    Drug Discov Today; 2012 Apr; 17(7-8):285-90. PubMed ID: 22033197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to optimize brain penetration in drug discovery.
    Liu X; Chen C
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):505-12. PubMed ID: 16022187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes.
    Zhao YH; Abraham MH; Ibrahim A; Fish PV; Cole S; Lewis ML; de Groot MJ; Reynolds DP
    J Chem Inf Model; 2007; 47(1):170-5. PubMed ID: 17238262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography.
    Yoon CH; Kim SJ; Shin BS; Lee KC; Yoo SD
    J Biomol Screen; 2006 Feb; 11(1):13-20. PubMed ID: 16314407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain.
    Pardridge WM
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):683-91. PubMed ID: 14579518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening.
    Culot M; Lundquist S; Vanuxeem D; Nion S; Landry C; Delplace Y; Dehouck MP; Berezowski V; Fenart L; Cecchelli R
    Toxicol In Vitro; 2008 Apr; 22(3):799-811. PubMed ID: 18280105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison.
    Carrara S; Reali V; Misiano P; Dondio G; Bigogno C
    Int J Pharm; 2007 Dec; 345(1-2):125-33. PubMed ID: 17624703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling blood-brain barrier partitioning using Bayesian neural nets.
    Winkler DA; Burden FR
    J Mol Graph Model; 2004 Jul; 22(6):499-505. PubMed ID: 15182809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind".
    Goodwin JT; Clark DE
    J Pharmacol Exp Ther; 2005 Nov; 315(2):477-83. PubMed ID: 15919767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly profiling blood-brain barrier penetration with liposome EKC.
    Wang Y; Sun J; Liu H; He Z
    Electrophoresis; 2007 Jul; 28(14):2391-5. PubMed ID: 17578839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling of the blood-brain barrier in drug discovery and development.
    Cecchelli R; Berezowski V; Lundquist S; Culot M; Renftel M; Dehouck MP; Fenart L
    Nat Rev Drug Discov; 2007 Aug; 6(8):650-61. PubMed ID: 17667956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.
    Lacombe O; Videau O; Chevillon D; Guyot AC; Contreras C; Blondel S; Nicolas L; Ghettas A; Bénech H; Thevenot E; Pruvost A; Bolze S; Krzaczkowski L; Prévost C; Mabondzo A
    Mol Pharm; 2011 Jun; 8(3):651-63. PubMed ID: 21438632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.